Literature DB >> 9375924

Metacarpophalangeal analysis in Crouzon syndrome: additional evidence for phenotypic convergence with the acrocephalosyndactyly syndromes.

C A Murdoch-Kinch1, R E Ward.   

Abstract

Crouzon syndrome (CS) is characterized by premature craniosynostosis, orbital proptosis, and midfacial hypoplasia and is related to the acrocephalosyndactylies (ACS) with limb abnormalities. In CS the hands are considered to be normal, but a previous report indicated that there is consistent alteration in the proportions of the bones of the hands, as shown by metacarpophalangeal analysis (MCPP), in at least some cases of CS. The purpose of this study was to extend these findings by examining affected individuals and their supposedly unaffected first degree relatives. If CS does have an effect on hands, then this should only be evident in the affected individuals and, presuming complete penetrance, not present in their unaffected relatives. PA hand films were taken on 12 CS subjects and 16 of their normal relatives. The lengths of the metacarpals and phalanges were measured and the measurements standardized for age and sex by conversion to z-scores using published normal standards. Mean pattern profiles for the 2 groups were plotted. In CS the phalanges, especially the first and second proximal phalanges and the first distal phalanx, were shorter than average, and shorter than those of unaffected relatives. The metacarpals were not significantly smaller than the reference means in CS. The 19 hand measurements were entered into a stepwise forward discriminant function analysis (DFA) to develop a model that would discriminate between CS subjects and their normal first degree relatives. The function generated used the measurements of 8 hand bones to classify correctly CS subjects and their normal relatives 100% of the time. This study confirmed that there is a radiographically detectable abnormality of the hands in CS and that, at least in this sample, relatives did not display such abnormalities. Therefore, it seems that CS shares postcranial effects with true ACS and that these effects are, like the other aspects of CS, fully penetrant.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9375924

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  6 in total

1.  FGFR2 mutation in a Chinese family with unusual Crouzon syndrome.

Authors:  Zi-Li Li; Xue Chen; Wen-Juan Zhuang; Wei Zhao; Ya-Ni Liu; Fang-Xia Zhang; Ruo-Shui Ha; Jin-Hua Wu; Chen Zhao; Xun-Lun Sheng
Journal:  Int J Ophthalmol       Date:  2016-10-18       Impact factor: 1.779

Review 2.  Craniosynostosis as a clinical and diagnostic problem: molecular pathology and genetic counseling.

Authors:  Anna Kutkowska-Kaźmierczak; Monika Gos; Ewa Obersztyn
Journal:  J Appl Genet       Date:  2018-02-01       Impact factor: 3.240

3.  Germline and somatic mosaicism for FGFR2 mutation in the mother of a child with Crouzon syndrome: Implications for genetic testing in "paternal age-effect" syndromes.

Authors:  Anne Goriely; Helen Lord; Jasmine Lim; David Johnson; Tracy Lester; Helen V Firth; Andrew O M Wilkie
Journal:  Am J Med Genet A       Date:  2010-08       Impact factor: 2.802

4.  Fibroblast growth factor (FGF) signaling in development and skeletal diseases.

Authors:  Chad M Teven; Evan M Farina; Jane Rivas; Russell R Reid
Journal:  Genes Dis       Date:  2014-12-01

5.  Syndrome diagnosis: human intuition or machine intelligence?

Authors:  Oivind Braaten; Johannes Friestad
Journal:  Open Med Inform J       Date:  2008-11-19

6.  Mutations in the interleukin receptor IL11RA cause autosomal recessive Crouzon-like craniosynostosis.

Authors:  Katharina Keupp; Yun Li; Ibrahim Vargel; Alexander Hoischen; Rebecca Richardson; Kornelia Neveling; Yasemin Alanay; Elif Uz; Nursel Elcioğlu; Martin Rachwalski; Soner Kamaci; Gökhan Tunçbilek; Burcu Akin; Joachim Grötzinger; Ersoy Konas; Emin Mavili; Gerhard Müller-Newen; Hartmut Collmann; Tony Roscioli; Michael F Buckley; Gökhan Yigit; Christian Gilissen; Wolfram Kress; Joris Veltman; Matthias Hammerschmidt; Nurten A Akarsu; Bernd Wollnik
Journal:  Mol Genet Genomic Med       Date:  2013-08-19       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.